ReviewJournal of rheumatic diseases2026
Review of literature: posterior reversible encephalopathy syndrome in systemic lupus erythematosus.
Review in Journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a neuroradiological disorder primarily affecting the posterior circulation of the brain. It manifests with a spectrum of symptoms, typically accompanied by hypertension, headache, seizures, and blurred vision. The etiology of PRES remains uncertain, but it is believed to be associated with vasogenic edema. The underlying conditions can range from sepsis to drug-induced states, autoimmune diseases, systemic lupus erythematosus (SLE), which is the most prevalent connective tissue disease associated with PRES. SLE is a multisystemic disorder that impacts various organs in the body, with musculoskeletal and skin systems being the most affected. The morbidity and mortality associated with SLE stem from its potential involvement of life-threatening organs, including the central nervous system, kidneys, and respiratory system. This article will focus on the neurological impact of PRES, including its manifestations. The association between PRES and SLE will be discussed in detail, accompanied by a literature review that explores the variability of presentation, reversibility, and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.